Solid TumorHOPAYANCT05858424
Impact of a Multidisciplinary End-of-treatment Day Hospital on the Quality of Life of Adolescents and Young Adults With Cancer
A study testing Multidisciplinary day hospitalization in people with Solid Tumor and Lymphoma, run by Centre Leon Berard at 1 site in France.
Trial summary
Rational: 800 cases of cancer per year are diagnosed in France among Adolescents and Young Adults (AYA). This population has been specifically targeted since 2008 by the INCa, leading to the development of structures entirely dedicated to its management. Read more about this study
- Who is it for?
- Ages 15 to 25 years
- Conditions the study is for
- Solid Tumor, Lymphoma
- What is being tested?
- Multidisciplinary day hospitalization
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 214 participants
- Where
- 1 siteFrance
- Study dates
- 29 Nov 2022to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 25 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Be aged between 15 and 25 years at diagnosis. This age range corresponds to the one chosen at the Leon Berard comprehensive cancer care center (CLB) for support in the AYA Department.
- Be previously treated at the Paediatric Hematology and Oncology Institute (IHOPe) and/or at CLB in AYA Department
- For a solid tumor or a lymphoma
- Be in complete oncological response at the end of treatment; have received their end-of-treatment evaluation
- Have finished their therapy since less than 2 months (therapy is defined by any treatment received, including maintenance)
- Be capable of understanding, reading and writing French
Show all 9Show fewer
- Be affiliated to a health insurance plan
- Have been informed of the study and have consented to it
- For minor patients, consent of parents and/or legal tutors must be collected.
Who cannot join
- cannot be followed-up throughout the duration of the study (12 months),
- be deprived of liberty by a court or administrative decision,
- have not consent to participate or are incapable of objecting in an informed manner.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Véronique CHRISTOPHE, PU contact
France1 site, 1 recruiting
- Recruiting
Centre Leon Berard
Lyon, 69008
Amandine Bertrand, MD, +33478782606
About this study
Official title: Impact Evaluation of a Multidisciplinary End-of-treatment Day Hospital on the Quality of Life of Adolescents and Young Adults With Cancer
Rational: 800 cases of cancer per year are diagnosed in France among Adolescents and Young Adults (AYA). This population has been specifically targeted since 2008 by the INCa, leading to the development of structures entirely dedicated to its management. Indeed, the occurrence of cancer in this period of transition leads to specific problems, which require a special attention. The various measures taken since then (Cancer Plan 2014-2019, DGOS instruction in 2016, 10-year strategy to fight cancer 2021-2030) have enabled the implementation of multidisciplinary structures, resulting in better access to care, and consideration of the social, family and relational dimensions of this population. However, the transition from the end of oncology treatment to the follow-up period remains a sensitive period, generating both positive (relief, joy) and negative feelings (uncertainty, feelings of abandonment, anxiety).
The investigators therefore hypothesize that the creation of a multidisciplinary end-of-treatment day hospital (DH) involving at least one medical interview, one psychological consultation and one social interview, would improve the quality of life of these former patients during the first year of oncology follow-up.
Read more
Method: This is a clinical research study conducted in a single centre. At their last visit for treatment, the study will be offered to patients. If the participants agree to participate, they will be randomized to benefit from DH in addition to their planned follow-up with their oncologist. The main objective is to compare the quality of life of former patients according to participation in DH or not. 210 patients will be included for a 20-month recruitment period.
Expected results: Throughout the development of DH, the investigators plan to improve the quality of life of former patients during this transitional phase.
Read the detailed description
HOPAYA is a monocentric open-label clinical research with 2 parallel groups. Patients will be 1:1 randomly assigned in both groups.
The main objective of the study is to compare the evolution of the health-related quality of life of former patients who have benefited of a multidisciplinary day hospitalization to those who only had standard oncological follow-up during the first year after cancer treatment completion.
The secondary objectives are:
- to evaluate and compare the anxiety and depression level in both groups (with or without day hospitalization);
- to evaluate emotional competence in both groups (with or without day hospitalization);
- to evaluate the satisfaction about the multidisciplinary day hospitalization.
This study will be presented to patients (and their parents/legal tutors in case of minor patients) during the last visit for any treatment, by coordinating nurses of AYA Department and/or by the adult or pediatric oncologist. At the same time, the information sheet with the consent form will be provided in order to give them a reasonable time for reflection.
After the collection of the consent form for the conduct of the study, former patients will be randomly assigned in 2 groups, with or without multidisciplinary day hospitalization.
- Group A : former patients with multidisciplinary day hospitalization In this group, a multidisciplinary day hospitalization will be programmed after the end-of-treatment evaluation and 2 months after the end of treatment at the latest. This day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. The medical interview will be conducted by a clinician researcher, specialised in long-term care after cancer. The objectives of this medical interview are to summarize the pathology, the treatment(s) received, and to develop a personalized after-cancer plan. The doctor will carry out both a clinical and an overall assessment of the patient, by wide-ranging questioning covering educational/professional, social, dietetic, addictology and physical fields. This medical interview is complementary to oncological follow-up, which consists of monitoring relapse and possible sequelae.
The psychological interview will be carried out if possible by the psychologist who followed the former patient during his/her treatment. The psychologist will assess the needs for further care, and will refer the former patient if necessary.
The social interview will be carried out by the social worker of AYA department. The social worker will take stock of the former patient's return to school and/or professional life, and direct him/her to possible applications for social assistance if needed.
If needs of supportive care emerge from the history of treatment period, some consultations can be added during the day hospitalization, like an interview with a dietician or an adapted physical activity assessment.
- Group B : former patients without multidisciplinary day hospitalization In this group, the former patients will experiment the standard of care, with an oncological follow-up.
The investigators expect that the AYAs' participation to the hospitalization day will positively impact their health-related quality of life compared to those who haven't participated. The investigators also expect that emotional competence will be explicative of the HRQoL through the mediation of the anxiety and depression levels.
Through the development of a multidisciplinary end-of-treatment day hospitalization, health care professionals plan to improve the quality of life of former patients during this transition phase of completing treatment. The lack of information on both medical and psychosocial long-term effects, will be improved by early and specific support. The feeling of abandonment often felt by former patients should decrease.
In addition, the early introduction of the long-term follow-up physician in the management of post-cancer, in parallel with the former patient's referring oncologist, should increase information and adherence to the personalized post-cancer plan.
The HOPAYA study aims to improve knowledge about the immediate quality of life after the treatment of AYAs with cancer, which is a challenge in this vulnerable population with specific needs. Comparison with the control group will make possible to highlight the specific impact of the establishment of a multidisciplinary end-of-treatment day hospitalization on quality of life. It will allow to target the flaws and shortcomings in AYA survivors support. The investigators also expect that the early screening of emotional competence will allow health care professionals to tailor support to the special needs of AYAs and their families.
Although many recommendations have emerged from the literature, to our knowledge, very few devices such this multidisciplinary day hospital have been elaborated for AYA early survivors of cancer. This study will evaluate the feasibility and the acceptability of a specific end-of-treatment hospitalization day for AYAs. The data collected and the analysed results in this study will allow to adapt and generalize this device in all AYAs' survivors in the CLB, and then at a larger level.
This study will lead to a scientific article published in an international journal, allowing the AYA hospitalization day to be reproduced in other oncologic centres and hospitals.
- Conditions
- Solid Tumor, Lymphoma
- Being tested
- Multidisciplinary day hospitalization
- Keywords
- Survivorship, Supportive care needs, Adolescents and Young Adults, Post-treatment, Oncology, Quality of life
- Medical subject headings
- Lymphoma, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multidisciplinary day hospitalizationOther
This multidisciplinary day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. The objectives of this medical interview, conducted by a clinician researcher, are to summarize the pathology, the treatment(s) received, and to develop a personalized after-cancer plan.
The psychological interview will assess the needs for further care, and will refer the former patient if necessary.
The social interview will take stock of the former patient's return to school and/or professional life, and direct him/her to possible applications for social assistance if needed.
If needs of supportive care emerge from the history of treatment period, some consultations can be added during the day hospitalization, like an interview with a dietician or an adapted physical activity assessment.
| Study group | Role | What they receive |
|---|---|---|
| Group A : former patients with multidisciplinary day hospitalization | Experimental | In this group, a multidisciplinary day hospitalization will be programmed after the end-of-treatment evaluation and 2 months after the end of treatment at the latest. This day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. Receives: Other: Multidisciplinary day hospitalization |
| Group B : former patients without multidisciplinary day hospitalization | No intervention | In this group, the former patients will experiment the standard of care, with an oncological follow-up. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Health-related Quality of life - emotional functioning
The PedsQL is a standardised, generic assessment of health-related perceptions of quality of life in paediatric patients. The PedsQL consists of 4 subscale scores (physical, emotional, social and school) and 3 summary scores (physical health, psychosocial health and total scale). All PedsQL scores range from 0 to 100, with higher scores indicating better quality of life.
Measured: 12 to 15 months after cancer treatment completion
Secondary outcomes (7)
To evaluate and compare the evolution of health-related quality of life at 12 months in the 2 groups
The evolution of the QOL at 12 months will be studied via all the dimensions of QOL of the PedsQL questionnaire which will be completed by the patients of the two groups at inclusion ( from 0 to 3 months after the end of the treatments), and at 12 months
Measured: from 0 to 3 months after the end of the treatments, and at 12 months after cancer treatment completion
To evaluate and compare the evolution of QOL over time in the two groups: longitudinal analysis
The evolution of QoL will be measured via all the QoL dimensions of the PedsQL questionnaire which will be completed by patients in both groups at inclusion (0 to 3 months after the end of treatment), and at 3, 6, 9 and 12 months
Measured: at inclusion (0 to 3 months after the end of treatment), and at 3, 6, 9 and 12 months after cancer treatment completion
To evaluate and compare the level of anxiety and depression in the 2 groups at inclusion (0 to 3 months after the end of treatment) and at 12 months
Anxiety and depression levels will be measured via the HADS questionnaire (Hospital Anxiety and Depression Scale) in the two groups (multidisciplinary DH in addition to standard oncology follow-up vs. standard oncology follow-up without multidisciplinary DH) at inclusion (0 to 3 months after the end of treatment) and at 12 months
Measured: at inclusion (0 to 3 months after the end of treatment) and at 12 months after cancer treatment completion
To evaluate and compare the emotional regulation difficulties of the AYAs in the 2 groups at inclusion (0 to 3 months after the end of treatment) and at 12 months
Emotional regulation strategies will be measured using the DERS scale (Difficulties in Emotion Regulation Scale), in both groups (multidisciplinary DH in addition to standard oncological follow-up vs. standard oncological follow-up without multidisciplinary DH) at inclusion (0 to 3 months after the end of treatment) and at 12 months
Measured: at inclusion (0 to 3 months after the end of treatment) and at 12 months after cancer treatment completion
To describe the compliance of the AJAs to the multidisciplinary DH vs. to the standard oncological follow-up without multidisciplinary DH, and to the proposed medical and paramedical orientations
Compliance with follow-up will be described in the DH group by the number of DH proposed and actually performed (harvesting of the number of refusals and no-shows), as well as by the number and type of medical and paramedical consultations scheduled and actually performed in the two groups during the 12 months of follow-up
- Group A: number of patients summoned to DH/number of DH carried out
- Group A: oral reason for non-acceptance of the DH
- Group A and B: number of patients called for the first oncology follow-up visit/number of visits made
- Groups A and B: number and type of medical and paramedical consultations scheduled and actually performed during the 12 months of follow-up.
Measured: 12 months after cancer treatment completion
To describe the sequelae of the AJA in the 2 groups at inclusion (0 to 3 months after the end of treatment) and at 12 months
Sequelae will be described via the collection of clinical data carried out in the 2 groups (multidisciplinary DH in addition to the standard oncological follow-up vs. standard oncological follow-up without multidisciplinary DH) at inclusion (0 to 3 months after the end of treatment) and at 12 months
Measured: at inclusion (0 to 3 months after the end of treatment) and at 12 months after cancer treatment completion
To evaluate the satisfaction of the AJAs who participate in the multidisciplinary DH following it
Satisfaction with the DH will be assessed by means of a 10-point visual analogue scale completed by the AJAs following their participation in the DH
Measured: Immediately after the multidisciplinary DH
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2023
- Study start29 Nov 2022
- Primary completionJul 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Solid TumorStudies of the same condition, open and under way.
- More trials run by Centre Leon BerardThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is a monocentric open-label clinical research with 2 parallel groups. Patients will be 1:1 randomly assigned in both groups. * Group A : former patients with multidisciplinary day hospitalization * Group B : former patients without multidisciplinary day hospitalization
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 214 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Leon Berard
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Amandine BERTRAND, MD, Principal investigator, Institut d'Hématologie et d'Oncologie Pédiatrique
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05858424
- Sponsor's protocol ID
- ET22000179
- Acronym
- HOPAYA
- Status last verified
- Apr 2026
- First submitted
- 20 Oct 2022
- Last updated
- 22 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact Evaluation of a Multidisciplinary End-of-treatment Day Hospital on the Quality of Life of Adolescents and Young Adults With Cancer
- ClinicalTrials.gov ID
- NCT05858424
- Acronym / sponsor ID
- HOPAYA / ET22000179
- Conditions
- Solid Tumor, Lymphoma
- Keywords
- Survivorship, Supportive care needs, Adolescents and Young Adults, Post-treatment, Oncology, Quality of life
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 214 participants (estimated)
- Lead sponsor
- Centre Leon BerardUniversity, hospital or other
- Study start
- 29 Nov 2022 (actual)
- Primary completion
- Jul 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 15 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rational: 800 cases of cancer per year are diagnosed in France among Adolescents and Young Adults (AYA). This population has been specifically targeted since 2008 by the INCa, leading to the development of structures entirely dedicated to its management. Indeed, the occurrence of cancer in this period of transition leads to specific problems, which require a special attention. The various measures taken since then (Cancer Plan 2014-2019, DGOS instruction in 2016, 10-year strategy to fight cancer 2021-2030) have enabled the implementation of multidisciplinary structures, resulting in better access to care, and consideration of the social, family and relational dimensions of this population. However, the transition from the end of oncology treatment to the follow-up period remains a sensitive period, generating both positive (relief, joy) and negative feelings (uncertainty, feelings of abandonment, anxiety).
The investigators therefore hypothesize that the creation of a multidisciplinary end-of-treatment day hospital (DH) involving at least one medical interview, one psychological consultation and one social interview, would improve the quality of life of these former patients during the first year of oncology follow-up.
Method: This is a clinical research study conducted in a single centre. At their last visit for treatment, the study will be offered to patients. If the participants agree to participate, they will be randomized to benefit from DH in addition to their planned follow-up with their oncologist. The main objective is to compare the quality of life of former patients according to participation in DH or not. 210 patients will be included for a 20-month recruitment period.
Expected results: Throughout the development of DH, the investigators plan to improve the quality of life of former patients during this transitional phase.
Detailed description
HOPAYA is a monocentric open-label clinical research with 2 parallel groups. Patients will be 1:1 randomly assigned in both groups.
The main objective of the study is to compare the evolution of the health-related quality of life of former patients who have benefited of a multidisciplinary day hospitalization to those who only had standard oncological follow-up during the first year after cancer treatment completion.
The secondary objectives are:
- to evaluate and compare the anxiety and depression level in both groups (with or without day hospitalization);
- to evaluate emotional competence in both groups (with or without day hospitalization);
- to evaluate the satisfaction about the multidisciplinary day hospitalization.
This study will be presented to patients (and their parents/legal tutors in case of minor patients) during the last visit for any treatment, by coordinating nurses of AYA Department and/or by the adult or pediatric oncologist. At the same time, the information sheet with the consent form will be provided in order to give them a reasonable time for reflection.
After the collection of the consent form for the conduct of the study, former patients will be randomly assigned in 2 groups, with or without multidisciplinary day hospitalization.
- Group A : former patients with multidisciplinary day hospitalization In this group, a multidisciplinary day hospitalization will be programmed after the end-of-treatment evaluation and 2 months after the end of treatment at the latest. This day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. The medical interview will be conducted by a clinician researcher, specialised in long-term care after cancer. The objectives of this medical interview are to summarize the pathology, the treatment(s) received, and to develop a personalized after-cancer plan. The doctor will carry out both a clinical and an overall assessment of the patient, by wide-ranging questioning covering educational/professional, social, dietetic, addictology and physical fields. This medical interview is complementary to oncological follow-up, which consists of monitoring relapse and possible sequelae.
The psychological interview will be carried out if possible by the psychologist who followed the former patient during his/her treatment. The psychologist will assess the needs for further care, and will refer the former patient if necessary.
The social interview will be carried out by the social worker of AYA department. The social worker will take stock of the former patient's return to school and/or professional life, and direct him/her to possible applications for social assistance if needed.
If needs of supportive care emerge from the history of treatment period, some consultations can be added during the day hospitalization, like an interview with a dietician or an adapted physical activity assessment.
- Group B : former patients without multidisciplinary day hospitalization In this group, the former patients will experiment the standard of care, with an oncological follow-up.
The investigators expect that the AYAs' participation to the hospitalization day will positively impact their health-related quality of life compared to those who haven't participated. The investigators also expect that emotional competence will be explicative of the HRQoL through the mediation of the anxiety and depression levels.
Through the development of a multidisciplinary end-of-treatment day hospitalization, health care professionals plan to improve the quality of life of former patients during this transition phase of completing treatment. The lack of information on both medical and psychosocial long-term effects, will be improved by early and specific support. The feeling of abandonment often felt by former patients should decrease.
In addition, the early introduction of the long-term follow-up physician in the management of post-cancer, in parallel with the former patient's referring oncologist, should increase information and adherence to the personalized post-cancer plan.
The HOPAYA study aims to improve knowledge about the immediate quality of life after the treatment of AYAs with cancer, which is a challenge in this vulnerable population with specific needs. Comparison with the control group will make possible to highlight the specific impact of the establishment of a multidisciplinary end-of-treatment day hospitalization on quality of life. It will allow to target the flaws and shortcomings in AYA survivors support. The investigators also expect that the early screening of emotional competence will allow health care professionals to tailor support to the special needs of AYAs and their families.
Although many recommendations have emerged from the literature, to our knowledge, very few devices such this multidisciplinary day hospital have been elaborated for AYA early survivors of cancer. This study will evaluate the feasibility and the acceptability of a specific end-of-treatment hospitalization day for AYAs. The data collected and the analysed results in this study will allow to adapt and generalize this device in all AYAs' survivors in the CLB, and then at a larger level.
This study will lead to a scientific article published in an international journal, allowing the AYA hospitalization day to be reproduced in other oncologic centres and hospitals.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- This study is a monocentric open-label clinical research with 2 parallel groups. Patients will be 1:1 randomly assigned in both groups. * Group A : former patients with multidisciplinary day hospitalization * Group B : former patients without multidisciplinary day hospitalization
| Arm | Type | Receives |
|---|---|---|
| Group A : former patients with multidisciplinary day hospitalization | Experimental | Other: Multidisciplinary day hospitalizationIn this group, a multidisciplinary day hospitalization will be programmed after the end-of-treatment evaluation and 2 months after the end of treatment at the latest. This day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. |
| Group B : former patients without multidisciplinary day hospitalization | No intervention | –In this group, the former patients will experiment the standard of care, with an oncological follow-up. |
Who may qualify
- Ages
- 15 to 25 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (9 listed)
- Be aged between 15 and 25 years at diagnosis. This age range corresponds to the one chosen at the Leon Berard comprehensive cancer care center (CLB) for support in the AYA Department.
- Be previously treated at the Paediatric Hematology and Oncology Institute (IHOPe) and/or at CLB in AYA Department
- For a solid tumor or a lymphoma
- Be in complete oncological response at the end of treatment; have received their end-of-treatment evaluation
- Have finished their therapy since less than 2 months (therapy is defined by any treatment received, including maintenance)
Key exclusion criteria (3 listed)
- cannot be followed-up throughout the duration of the study (12 months),
- be deprived of liberty by a court or administrative decision,
- have not consent to participate or are incapable of objecting in an informed manner.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multidisciplinary day hospitalizationThis multidisciplinary day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. The objectives of this medical interview, conducted by a clinician researcher, are to summarize the pathology, the treatment(s) received, and to develop a personalized after-cancer plan. The psychological interview will assess the needs for further care, and will refer the former patient if necessary. The social interview will take stock of the former patient's return to school and/or professional life, and direct him/her to possible applications for social assistance if needed. If needs of supportive care emerge from the history of treatment period, some consultations can be added during the day hospitalization, like an interview with a dietician or an adapted physical activity assessment. | Other | Group A : former patients with multidisciplinary day hospitalization |
Primary outcome
Health-related Quality of life - emotional functioning
Time frame: 12 to 15 months after cancer treatment completion
The PedsQL is a standardised, generic assessment of health-related perceptions of quality of life in paediatric patients. The PedsQL consists of 4 subscale scores (physical, emotional, social and school) and 3 summary scores (physical health, psychosocial health and total scale). All PedsQL scores range from 0 to 100, with higher scores indicating better quality of life.
7 secondary outcomes
To evaluate and compare the evolution of health-related quality of life at 12 months in the 2 groups
Time frame: from 0 to 3 months after the end of the treatments, and at 12 months after cancer treatment completion
To evaluate and compare the evolution of QOL over time in the two groups: longitudinal analysis
Time frame: at inclusion (0 to 3 months after the end of treatment), and at 3, 6, 9 and 12 months after cancer treatment completion
To evaluate and compare the level of anxiety and depression in the 2 groups at inclusion (0 to 3 months after the end of treatment) and at 12 months
Time frame: at inclusion (0 to 3 months after the end of treatment) and at 12 months after cancer treatment completion
To evaluate and compare the emotional regulation difficulties of the AYAs in the 2 groups at inclusion (0 to 3 months after the end of treatment) and at 12 months
Time frame: at inclusion (0 to 3 months after the end of treatment) and at 12 months after cancer treatment completion
To describe the compliance of the AJAs to the multidisciplinary DH vs. to the standard oncological follow-up without multidisciplinary DH, and to the proposed medical and paramedical orientations
Time frame: 12 months after cancer treatment completion
To describe the sequelae of the AJA in the 2 groups at inclusion (0 to 3 months after the end of treatment) and at 12 months
Time frame: at inclusion (0 to 3 months after the end of treatment) and at 12 months after cancer treatment completion
To evaluate the satisfaction of the AJAs who participate in the multidisciplinary DH following it
Time frame: Immediately after the multidisciplinary DH
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2026.
Related trials for Solid Tumor
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
Active, not recruitingPhase 3
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Solid Tumors
RecruitingPhase 1
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies
RecruitingObservational study
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Véronique CHRISTOPHE, PU contact
Amandine BERTRAND, MD principal investigator
Institut d'Hématologie et d'Oncologie Pédiatrique
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multidisciplinary day hospitalization in people with Solid Tumor and Lymphoma, run by Centre Leon Berard at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amandine BERTRAND, MD (04787872606 ext. +33, Amandine.BERTRAND@ihope.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Health-related Quality of life - emotional functioning (time frame: 12 to 15 months after cancer treatment completion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.